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Abstract
Purpose: The purpose of this study is to investigate the dose-volume variations of planning target volume (PTV) and or-
gans-at-risk (OARs) in prostate volumetric modulated arc therapy (VMAT) when varying collimator angle. The collimator
has the largest impact and is worth considering, so, its awareness is essential for a planner to produce an optimal prostate VMAT
plan in a reasonable time frame. Methods: Single-arc VMAT plans at different collimator angles (0o, 15o, 30o, 45o, 60o, 75o and
were created systematically using a Harold heterogeneous pelvis phantom. The conformity index (CI), homogeneity index (HI),
gradient index (GI), machine monitor units (MUs), dose-volume histogram and mean and maximum dose of the PTV were cal-
culated and analyzed. On the other hand, the dose-volume histogram and mean and maximum doses of the OARs such as the
bladder, rectum and femoral heads for different collimator angles were determined from the plans. Results: There was no sig-
nificant difference, based on the planned dose-volume evaluation criteria, found in the VMAT optimizations for all studied
collimator angles. A higher CI (0.53) and lower HI (0.064) were found in the 45o collimator angle. In addition, the 15o
angle provided a lower value of HI similar to the 45o collimator angle. Collimator angles of 75o and 90o were found to be good
rectum sparing, and collimator angles of 75o and 30o were found to be good for sparing of right and left femur, respectively. The
PTV dose coverage for each plan was comparatively independent of the collimator angle. Conclusion: Our study indicates that
the dosimetric results provide support and guidance to allow the clinical radiation physicists to make careful decisions in im-
plementing suitable collimator angles to improve the PTV coverage and OARs sparing in prostate VMAT.
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Introduction
Volumetric modulated arc therapy (VMAT) has become a
standard delivery option in the field of prostate radiotherapy,
due to its shortened delivery time and the smaller monitor
units (MUs), as compare to step-and-shoot intensity modu-
lated radiotherapy (IMRT).1-6 Patient dosimetry between
prostate VMAT and IMRT has been extensively studied,
which reveals that prostate VMAT can produce comparable
or even improved target coverage and normal tissue (blad-
der, rectum and femoral heads) sparing.7-11
VMAT encloses more dose delivery parameters such as dy-
namic multileaf collimator movement, dose rate, and gantry
speed with single or multiple photon arcs in the treatment,
12-15which requires a more powerful machine, patient quality
assurance procedures, dose calculation algorithm, and dosi-
metric evaluation for the treatment.16-19
Until the availability of the Elekta linear accelerator VMAT
in 200820, the only commercially available treatment plan-
ning system (TPS) was ERGO++ (3D Line Medical Systems/
Elekta Ltd, Crawley, UK), which needed an initial definition
of sub-arcs and had manual version of the multileaf collima-
tor (MLC) before automatic weight optimization and was not
considered a full inverse planning system.11, 21 ,22 In December
2009, two manufacturers introduced a new system of VMAT
delivery that employed a VMAT treatment planning tool,
implemented in Oncentra with Master-plan v3.3 (Nucletron
BV, Veenendal, The Netherlands) with VMAT application
on a Synergy linac (Elekta Ltd, Crawley, UK). Initially, the
Synergy linac was used for a limited number of patients.8, 23
RapidArc (Varian Medical Systems, Palo Alto, CA) is a
VMAT technique delivering radiation dose over one or sev-
eral continuous arcs with the simultaneous adjustment of
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dose rate, gantry rotation speed, and multi-leaf collimator
(MLC) field aperture. RapidArc has gained enormous interest
because of its potential in delivering quality dose distribution
with significantly shortened treatment time and lower
number of MU. Several recent studies have reported the use
of arc-based radiation dose delivery methods in prostate
cancer.5, 7, 11, 24-26
Multileaf collimators (MLC) are the best tool for beam shap-
ing, and an important way to minimize the absorbed dose to
healthy tissue and critical organs. They have moveable leaves
arranged in pairs that can block a certain part of beam. Ow-
ing to its ability to control leaf position and with a large
number of controlled leaves, it can be used to shape any de-
sired field.27 Its manufacturers have established the necessary
mechanisms for precision, control and reliability, together
with reduction of leakage and transmission of radiation be-
tween and through the leaves. Moreover, it provides precise
dose delivery to any part or the treated volume, accurately.28
Otto has stated3 and later on approved29 that a 45o collimator
angle is feasible dosimetrically in most cases. While, Bort-
field et al.29 found that the superiority of the above collima-
tor angle (45o) was ambiguous. Furthermore, Bortfield and
Webb did their work with a 0o collimator angle for a 2D
model.30
Treutwein et al.31 concluded that the approximation was still
effective for 4° gantry spacing and same passing rates were
found for IMRT. The work of Feygelman et al.32and Bzdusek
et al.4 revealed that good dosimetric results were found with
minimum calculation time for 4° gantry spacing. So, for the
best maximum dose to the PTV and for good dosimetric re-
sults 4o gantry spacing was used in this study.
For this collimator angle analysis, in addition to dosimetry
(dose-volume criteria, mean and maximum dose), CI, HI, GI
and MU, comparison among different collimator angles such
as 0o, 15o, 30o, 45o, 60o, 75o and 90o for smart-arc VMAT have
been scrutinized. The aim of this study is to find the best
collimator angle for coverage of the PTV and sparing of
OARs. The results of this study will help to inform planners
in choosing the appropriate collimator angle.
Methods and Materials
Planning schemes
This study was established in order to compare dose distribu-
tion among different collimator angles (0o, 15o, 30o, 45o, 60o,
75o and 90o) focusing on the PTV and OARs. For each change
of collimator angle, a new plan was re-optimized for that
angle. The prescription dose was 78 Gy per 39 fractions. The
treatment plan was not changed for each angle, only repeated
by changing the collimator angles. The prostate Harold
phantom developed by Chiarot et al.33 was used for this
study. Computed tomography (CT) images (2 mm slice
thickness and slice interval) were taken from the Toshiba
scanner (Aquilion ONE TSX-301A; Toshiba medical systems,
USA) containing 512 × 512 pixels in each slice. The Harold
phantom was irradiated by a 120 kV photon beam with 300
mA current perpendicular to the phantom surface. After the
CT simulation, digital imaging and communication in medi-
cine (DICOM) CT images were transferred to the Pinnacle
treatment planning system (TPS) for contouring and plan-
ning preparation.
The rectum, bladder, PTV, and femoral heads were con-
toured on the TPS. The whole prostate was assigned as gross
tumor volume (GTV). The PTV was drawn by expanding 1
cm around the CTV in all directions uniformly except in the
posterior direction, where an expansion of 0.7 mm was per-
formed for a total contoured volume of 85.89 cm3. The blad-
der, rectum, and femoral heads have contoured volumes of
59.83 cm3, 36.26 cm3 and 166 cm3, respectively.
VMAT plan and treatment delivery
For planning the data, a Synergy S® linear accelerator with
energy of 6 MV, equipped with beam modulator head, an
iViewGT electronic portal imaging device, and on board
cone beam CT XVI was used for VMAT delivery. There were
no moveable jaws and the maximum field size was 16 cm ×
21 cm. Maximum variable dose rate for each VMAT plan was
600MU/min and the gantry was rotated from 180 to 179.9 in
the clockwise direction with 91 control points.
Smart-arc prostate VMAT plans were generated on Pinnacle
(Philips, Version 9.2.0, Fitchburg, WI, U.S.A) with AC-
QSim3TM and were optimized with the direct machine pa-
rameter optimization (DMPO) algorithm. The isocenter was
positioned at the center of the CTV and plans were set up in
39 fractions for 78 Gy minimum doses to the CTV. All cal-
culations were performed using adaptive convolve (AC)
having a calculation grid spacing of 0.25 cm. In order to
make fair comparisons, no modification was done through-
out the optimization to the dose-volume constraints and
weighting.
Dosimetric evaluation
The dosimetric comparison was carried out using the fol-
lowing parameters such as D99%, D95%, D5%, maximum dose
(Dmax), mean dose (Dmean), Conformity Index (CI), Homoge-
neity Index (HI), Gradient index (GI) and MUs for the PTV
for collimator angle as shown in Table 1.
By definition, RTOG CI (98) is the volume of the target re-
ceiving > 98% of the prescribe dose divided by the volume of
the PTV which has optimal value of 1. HI is defined as the
dose received by 5% of the PTV minus the dose received by
95% of the PTV divided by the mean dose (its optimal value
is 0) as shown in Equation (1).34
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meanD
DDHI %95%5  …..……. (1)
GI is defined as the ratio of volume covered by at least a given
percentage of the prescription dose.35Mathematically, GI in




VGI  ………………….... (2)
where, V50 is the volume covered by the at least 50% of the
prescription dose. A value closer to unity embodies a faster
dose fall-off in normal tissue, which may indicate a lower
dose to critical structure.
Dose-volume histogram (DVH) evaluation
Dose-volume histogram plots were used to provide quantita-
tive comparisons among the VMAT plans using the different
collimator angles. Considerable attention should be placed
on ensuring an unbiased comparison for successive computa-
tion of numerous indices. The DVHs data for each collimator
angle was gathered from Pinnacle with a bin size of 0.01 Gy.
PTV and organ specific individual DVHs for each collimator
angles were calculated.
Results
This study has been carried out on a Harold phantom and
clinically acceptable VMAT plans satisfying a minimum of
99% prescribed coverage to PTV were achieved. Mean doses
for all collimator angles were found between 75.96 (Gy) and
76.42 (Gy). The values of CI for all collimator angles are
summarized in Table 1 revealing that a 45o collimator angle
is closer to unity than any other studied collimator angles. A
collimator angle of 0o requires fewer MUs while 75o and 90o
collimator angles require the most MUs. The highest HI val-
ues were established for a 60o collimator angle whereas we
found lower values for 45o and 15o angles. It was found that a
30o collimator angle showed as lower GI value of GI that was
closer to unity while higher values were found at 0o collima-
tor angle. Figure 1 showes Dose distribution at collimator 90.
TABLE 1: Dosimetric results for PTV for all collimator angles.
Collimator angles 0o 15o 30o 45o 60o 75o 90o
D99% (Gy) 72.41 72.59 72.40 72.60 72.40 72.61 72.73
D5% (Gy) 78.44 78.44 78.79 78.55 78.96 78.86 78.40
D95% (Gy) 73.47 73.50 73.38 73.63 73.34 73.71 73.58
Dmax (Gy) 79.40 79.24 79.89 79.87 79.62 80.41 79.40
Dmean (Gy) 76.20 76.25 76.28 76.38 76.24 76.42 75.96
CI 0.49 0.51 0.51 0.53 0.48 0.52 0.37
HI 0.06 0.064 0.07 0.064 0.073 0.065 0.066
GI 7.9 7.6 4.97 5.5 5.7 5.4 9.4
MUs 351 352 365 356 362 364 366
FIG. 1: Dose distribution at collimator 90.
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FIG. 2: Average dose-volume histogram of the PTV.
FIG. 3(a): Average dose-volume histogram of the bladder.
FIG. 3(b): Average dose-volume histogram of the rectum.
FIG.4(a): Average dose-volume histogram of the Left femur.
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FIG. 4(b): Average dose-volume histogram of the right femur.
TABLE 2: Mean dose-volume criteria, average mean and maximum doses of the critical organs for VMAT plans at different collimator angles.
V30Gy, V38Gy,V14Gy, and V22Gy are percentage volume receiving at least 30 Gy, 38 Gy, 14 Gy, and 22 Gy, respectively. D50%,D30%,D5% are the doses
given to 50%, 30% and 5% of the volumes, respectively.
Collimator angles 0o 15o 30o 45o 60o 75o 90o
Rectum
Dmean (Gy) 53.69 53.56 52.59 53.62 52.05 53.61 52.29
Dmax (Gy) 79.13 79.09 79.77 79.87 79.62 79.92 79.12
D50% (Gy) 50.29 50.09 49.66 49.97 49.17 50.07 50.35
D30% (Gy) 68.33 68.39 68.07 69.14 68.93 68.66 69.25
V30Gy (%) 36.26 36.26 36.22 36.26 36.19 36.26 35.64
V38Gy (%) 35.43 35.96 33.07 35.3 31.69 34.76 31.67
Bladder
Dmean (Gy) 53.08 52.47 51.59 51.99 52.37 52.49 50.69
Dmax (Gy) 78.73 78.58 79.36 78.24 79.47 78.96 78.63
D50% (Gy) 50.40 49.33 49.31 48.92 48.69 50.59 50.00
D30% (Gy) 69.02 68.74 68.93 69.15 68.41 69.46 70.16
V30Gy (%) 59.84 59.69 58.12 59.53 59.84 57.31 54.40
V38Gy (%) 54.24 55.48 51.22 50.43 52.56 40.51 44.43
Left Femur
Dmean (Gy) 16.06 16.20 15.19 18.06 16.12 20.34 17.75
Dmax (Gy) 31.63 32.42 37.46 34.42 35.17 37.32 45.89
D5% (Gy) 27.13 28.32 29.27 29.86 30.05 32.50 35.54
V14Gy (%) 105.66 108.19 105.07 114.8 103.8 112.8 99.5
V22Gy (%) 95.65 91.40 69.20 100.98 75.18 107.64 80.02
Right Femur
Dmean (Gy) 17.32 17.34 16.33 14.92 15.14 14.33 22.73
Dmax (Gy) 37.06 39.05 40.62 40.08 40.80 43.55 54.14
D5% (Gy) 31.04 32.14 28.88 31.17 31.31 32.27 39.74
V14Gy (%) 108.68 111.12 107.56 100.17 102.69 95.87 117.4
V22Gy (%) 98.96 98.16 87.20 65.57 67.53 56.94 111.7
Average accumulated DVHs of the PTV, rectum, bladder and
femoral heads are shown in Figures 2-4, which are planned
using VMAT with different collimator angles. The planning
dose objectives of the rectum and bladder agree well with
the prescribed dose; their mean, maximum, D30% and D50%
doses are shown in Table 2. V14% and V38%were chosen since
they have been used as physics quality assurance evaluation
criteria at the Princess Margaret cancer center. V30% and V38%
were calculated for rectum as well as for bladder and are
shown in Table 2. The dose to the femoral heads was found
to be within the acceptable range; their mean, maximum,
D5%, V14% and V22% are calculated and shown in Table 2.
Discussion
Dose-volume indices
An investigation of the collimator angles reveals that a 45°
collimator angle has a 0.3% higher CI, 0.14% lower HI and
0.02% lower requires MUs than all other studied collimator
angles. According to Bortifield29 a 45o collimator angle is
preferred to 0o collimator angle. He also clarified the hy-
pothesis that the leaves of the MLC in a parallel opposed
beam move in and orthogonal direction and consequently
these beams are not terminated. Additionally, Otto36 ex-
plained that only a single leaf pair can be used to modulate
6 Isa et al.: Collimator angle dependence in prostate VMAT International Journal of Cancer Therapy and Oncology
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the intensity within a CT slice without collimator rotation
and secondly that an 8% lower MU requirement can be
found using a 45o collimator angle verses 0o angle. This also
explains the fact that with a 45° collimator angle, one can
irradiate the right and left side of the PTV as well add spare
the rectum and bladder in a fashion that is not possible with
a 0o angle. In our investigation, the number of MUs required
are (0.02%) lower using a collimator angle of 45° than when
using a collimator angle of 90o. Fogliata et al.37 suggested that
it might be surprising that higher MUs are not commonly
suggested to improve the plan excellency. Obviously, addi-
tional MUs are not always exploited in smaller MLC aper-
tures for better dose modulation. Verbakel et al.38 clearly
indicated that a 45o collimator angle permits satisfactory
PTV dose distributions by switching on and off the beam
from different directions.
Dose-volume criteria, maximum and mean dose
Mean dose-volume criteria, maximum and mean dose are the
important parameters for plan evaluation. Table 1 shows the
dosimetric results of the PTV and Table 2 summarizes the
mean dose-volume criteria of the bladder, rectum and femo-
ral heads calculated by the treatment planning system. In
this study the dose-volume evaluation criteria for the pros-
tate VMAT plan are: D99% of PTV ≥ 74.1Gy, D30% of rectum
and bladder ≤ 70Gy, D50% of rectum and bladder ≤ 53 Gy, D5%
of femoral heads ≤ 53Gy. For the mean D30% and D50%of the
rectum and bladder, all the collimator angles satisfy the cor-
responding dose-volume criteria. The mean D50% and D30%of
bladder are found to be lower for the 60o collimator angle
(on average 0.03% and 0.02%) than other studied collimator
angles. However, the 90o collimator angle had a higher D50%
and D30% for the rectum (on average 0.02% and 0.01%) than
other studied collimator angles. For the left and right femo-
ral head, the 90o collimator angle had a mean D5%which was
on average 0.23% and 0.9% higher more than the other col-
limator angles, respectively. For percentage bladder and rec-
tum volume receiving at least the given dose, lower V30%,
V38%, values were found using collimator angles of 90o and
60o, respectively. The percentage of the right and left femur
volume receiving at least the given dose was lower for the
V14Gy, V22Gy criteria at collimator angles of 75o and 30o, re-
spectively.
Dose-volume histogram
Figure 2 shows the average DVH of the PTV for all
collimator angles planned using the VMAT technique. The
dose range in Figure 2 begins at 70 Gy rather than 0 Gy to
focus on the drop-off region of the curve. No noticable
difference has been found using all studied collimator angles
as seen in Figure 2. It is obvious in Figure 3(a) that the per-
centage of volume receiving chosen doses (e.g. V30Gy and
V38Gy) are constantly lower for a 75o collimator angle. This
shows that collimator angle of 75o is good for bladder sparing
with V38Gy value is 40.51. It is apparent in the Figure 3(b)
that the percentage volume receving our choosen doses (e.g.
V30Gy and V38Gy) are always lower for a 90o collimator angle.
This shows that 90o collimator angle results in better rectum
sparing and its V38Gy value is 31.97. It can be seen thatV14Gy
and V22Gy are persistently lower for 75o collimator angle. This
shows that 75o collimator angle is good for sparing of the
right femur and its V22Gy value is 56.94. It can be realized in
Figure 4(b) that percentage volume receiving doses (e.g.
V14Gy and V22Gy) are persistently lower for the 30o collimator
angle. This shows that 30o collimator angle is suitable for left
femur sparing (its V22Gy value is 69.20).
For non-single arc prostate VMAT, Rana et al.39 found that it
is feasible to use a partial arc technique in a RapidArc pros-
tate plan. They showed that for the same PTV coverage and
plan optimization parameters, the partial arc technique de-
livered a higher dose to the femoral heads but lower doses to
the rectum, bladder, and penile bulb when compared to the
single arc technique. On the other hand, Sze et al.40 reported
that double arc technique could produce a better plan with
improved PTV coverage and reduced treatment time com-
pared to intensity modulated radiation therapy. They found
that though the single arc technique resulted in a higher
rectal dose, the technique had higher efficiency than the
double arc. For a busy treatment unit demanding high pa-
tient throughput, single arc technique could be an acceptable
option for simple prostate cases. However, for complex cases
involving lymph doses, more than one single full arc may be
required. It is worthwhile to study the collimator angle ef-
fect on different photon arc techniques in prostate VMAT.
This is the future work in this study.
Conclusion
This work explores the impact of different collimator angles
on a dosimetric scoring function. Collimator angle selection
could play vital role in improving the quality of treatment
plans. It is concluded from the results that the dose variations
with the change of collimator angle are significant. VMAT
plans with said collimator angles do not play a substantial
role in PTV coverage but for more accuracy, a 45o collimator
angle provides superior PTV dose distribution than all other
studied collimator angles as shown by a higher value of CI,
lower value of HI and 1.4% higher value of MUs. It was ob-
served that a 75o collimator angle appropriate for sparing of
rectum and right femur. In our investigation, 90o and 30o
collimator angles showed the highest sparing of the rectum
and left femur, respectively. The results of our study set the
groundwork for guiding the collimator angle selection with
regards to PTV dose distribution and sparing of OARs in
prostate VMAT planning. This work also can be extended to
other treatment sites using VMAT.
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